Portugal's Infarmed regulatory authority has pulled a German-imported burn treatment called Calmidine from Portuguese pharmacies and retail channels, determining the product was illegally marketed as a cosmetic when its therapeutic formulation demands classification as a medicine. The decision arrived in June 2026 as part of the country's regulatory enforcement on mislabeled health products.
Why This Matters
• If you own Calmidine: Stop using it immediately and dispose of the product safely. Infarmed has not issued a formal return requirement or refund program, but pharmacies are removing all inventory from shelves.
• The classification issue: Calmidine contains triolamine at 6.7 mg/g—a therapeutic agent linked to wound regeneration, radiation dermatitis, and skin repair. EU law treats such claims as pharmaceutical, not cosmetic, requiring clinical trials and pre-market authorization.
• No health crisis: The withdrawal stems entirely from regulatory non-compliance, not poisonings or adverse events. Zero reported injuries have triggered this action, making it an administrative safeguard rather than emergency response.
The Core Problem: Label Versus Reality
During a routine national market inspection, Infarmed's compliance officers concluded that Calmidine—produced by German distributor MedNet GmbH—does not meet the foundational requirements of EU Regulation 1223/2009, the uniform cosmetics standard across all 27 member states. The gap between marketing and legality is narrow but decisive.
Under European law, a cosmetic is narrowly defined: any substance intended for external bodily contact whose purpose is to clean, perfume, maintain appearance, or preserve condition. What it categorically cannot do is claim to treat, cure, or reverse medical conditions. Calmidine, however, is explicitly marketed for regeneration and intensive hydration following minor burns, sunburn, superficial wounds, insect bites, and secondary skin reactions from radiotherapy including erythema and scaling. Those claims cross into pharmaceutical territory.
The product's formulation reinforces the classification problem. The emulsion contains triolamine, water, liquid paraffin, glycol stearate, stearic acid, propylene glycol, paraffin, squalene, and oil. While individually these are not prohibited, their combined therapeutic intent—coating damaged skin to promote repair—automatically reclassifies the whole product.
What Consumers Should Know and Do
If Calmidine is in your medicine cabinet or bathroom drawer, the directive is straightforward: discontinue use now. The product may carry labeling in German, English, or Portuguese. Infarmed has not established a formal consumer recall scheme or reimbursement process; the priority is halting distribution and preventing further use.
Pharmacies, online retailers, and parapharmacy chains have been instructed to remove all Calmidine stock from their shelves and e-commerce platforms immediately. Retailers failing to comply face potential fines and regulatory sanctions. The withdrawal, it bears emphasizing, is not a response to documented consumer injury. No reported cases of allergic reactions, burns, treatment failures, or other adverse events triggered this action. The problem is purely regulatory: the product was commercialized under an incorrect legal framework.
Why This Matters Beyond the Label
The Calmidine episode highlights a recurring friction within the single European market. Products lawfully distributed in one member state—in this case, Germany—may face regulatory obstacles or outright prohibition in another, even when operating under supposedly uniform EU rules. Portugal's authorities retain discretionary enforcement powers in interpreting borderline cases, particularly when product marketing materials or formulations suggest therapeutic rather than cosmetic intent.
Expatriates and travelers accustomed to purchasing burn creams, anti-itch gels, or wound-care products from other countries should understand this reality: even if a product is legal in Spain, France, or the Netherlands, Portuguese customs and pharmacy inspectors can confiscate it or restrict its sale if deemed non-compliant with local interpretation of EU law. This creates practical friction for people who move across borders or shop across markets.
The Supply-Chain Reality
MedNet GmbH, headquartered in Germany, markets Calmidine and allied wellness products across multiple European countries. Under single-market principles, a product lawfully registered in one jurisdiction theoretically circulates freely throughout the EU. Reality diverges significantly. Regulatory discretion and varying enforcement intensity create a patchwork where the same formulation may be sold in Berlin, suspended in Lisbon, and untouched in Barcelona.
Portugal's decision does not trigger automatic withdrawals in neighboring Spain or France unless those nations' regulators independently reach similar conclusions. This creates confusion for manufacturers and consumers, particularly for niche products occupying the fuzzy boundary between cosmetics and pharmaceuticals.
Looking Forward: Stricter Oversight Ahead
Infarmed continues to maintain oversight of market surveillance, with particular focus on online sales channels, small importers, and products making therapeutic or medical claims. For manufacturers and distributors, the lesson is unambiguous: therapeutic claims trigger pharmaceutical scrutiny. Avoiding costly market withdrawals requires alignment between product dossiers, labeling, marketing materials, and the strict regulatory definition of a cosmetic. For residents, the takeaway is simpler: when a cream promises to heal, regenerate, or treat medical conditions, its regulatory status should be your first question, not your last.
